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Background—DNA topoisomerase inhibitors are commonly used for treating small cell lung 
cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this 
class of drugs and may therefore influence treatment outcome. In this study, we investigated 
whether common TDP1 single nucleotide polymorphisms (SNPs) are associated with overall 
survival among SCLC patients.
Methods—Two TDP1 SNPs (rs942190 and rs2401863) were analyzed in 890 patients from 10 
studies in the International Lung Cancer Consortium (ILCCO). The Kaplan-Meier method and 
Cox regression analyses were used to evaluate genotype associations with overall mortality at 36 
months post-diagnosis, adjusting for age, sex, race, and tumor stage.
Results—Patients homozygous for the minor allele (GG) of rs942190 had poorer survival 
compared to those carrying AA alleles, with a hazard ratio (HR) of 1.36 (95% confidence interval 
(CI): 1.08–1.72, p-value=0.01), but no association with survival was observed for patients carrying 
the AG genotype (HR=1.04, 95% CI:0.84–1.29, p-value=0.72). For rs2401863, patients 
homozygous for the minor allele (CC) tended to have better survival than patients carrying AA 
alleles (HR=0.79, 95% CI: 0.61–1.02, p-value=0.07). Results from the Genotype Tissue 
Expression (GTEx) Project, the Encyclopedia of DNA Elements (ENCODE), and the ePOSSUM 
web application support the potential function of rs942190.
Conclusions—We found the rs942190 GG genotype to be associated with relatively poor 
survival among SCLC patients. Further investigation is needed to confirm the result and to 
determine whether this genotype may be a predictive marker for treatment efficacy of DNA 
topoisomerase inhibitors.
Keywords
TDP1; polymorphism; survival; SCLC
Introduction
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer, with a 5-year 
survival of only 7% (1). Despite rapid advances in cancer therapy, treatment and overall 
survival of SCLC patients has changed little over the past few decades (2,3). Unlike non-
small cell lung cancer (NSCLC), in which several prognostic and predictive biomarkers have 
been identified and targeted clinically (4), there are relatively few markers to predict survival 
or to guide treatment selection for SCLC patients (reviewed in (2,5)).
A combination of platinum chemotherapy and a DNA topoisomerase inhibitor is the first-
line chemotherapy for treating SCLC patients (6). DNA topoisomerases (TOP1 and TOP2) 
are important players during DNA replication and transcription as they introduce transient 
DNA strand breaks (7). TOP1 inhibitors (e.g. Irinotecan, Topotecan) and TOP2 inhibitors 
(e.g. Etoposide, Teniposide) bind to DNA topoisomerases and generate drug-stabilized DNA 
cleavage complexes, which eventually result in tumor cell death (8,9). Tyrosyl-DNA 
phosphodiesterase (TDP1) plays a role in repairing both TOP1- and TOP2-mediated DNA 
damage (10,11) and it is believed to be responsible for drug resistance to DNA 
topoisomerase inhibitors (12,13). A study in SCLC cell lines suggests that the TDP1/TOP1 
ratio may be an indicator for the response of SCLC to Topotecan (14); however, 
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confirmation in SCLC tissue is lacking. Limited available tissue for such confirmation 
presents a challenge, since only a small portion of SCLC patients receive surgical resection.
Developing a blood-based marker to predict drug response would be useful to inform 
appropriate treatment for SCLC patients. Since TDP1 plays a role in resistance to DNA 
topoisomerase inhibitors, it is plausible that patients carrying a TDP1 variant may respond 
differently to treatment, thus having different survival outcomes. There are very few studies 
on TDP1 single nucleotide polymorphisms (SNP) (15–17) and, to the best of our knowledge, 
none have examined TDP1 SNPs in relation to SCLC survival. In this study, we investigated 
whether common TDP1 SNPs are associated with overall survival among SCLC patients in a 
multicenter study from the International Lung Cancer Consortium (ILCCO, http://
ilcco.iarc.fr).
Materials and methods
Study population
This study consists of 898 SCLC patients from 10 ILCCO studies that have data on patient 
survival time and vital status (Table 1). Further details on the study population and source of 
data for each study are provided in the Supplementary Text. All participants provided 
written informed consent, and each study was approved by its local institutional review 
board. For the current study, SCLC includes small cell carcinoma, combined small cell 
cancer, and neuroendocrine carcinoma (ICD-O 8013, 8041, 8042, 8043, 8044, 8045, 8246).
SNP selection and genotyping
Tag SNPs for the TDP1 gene region (± 2.5 kb of the coding sequence) were identified using 
the Genome Variation Server (http://gvs.gs.washington.edu). SNPs were classified into bins 
with a pairwise linkage disequilibrium (LD) threshold of r2 ≥ 0.8 using the IdSelect 
algorithm (18). The list of TDP1 tag SNPs based on HapMap Phase I and II Centre d’Etude 
du Polymorphism Humain (CEU) population was shown in the Supplementary Table S1. 
One SNP per bin of the tag SNPs with an average minor allele frequency (MAF) ≥ 5% (a 
total of six SNPs) was selected by prioritizing on the SNP function class and predicted 
genotyping success based on Illumina assay design score. Six TDP1 tag SNPs (rs9488, 
rs942190, rs1286927, rs2401863, rs4143999, and rs12880397) were genotyped on 1,586 
healthy controls and 793 lung cancer cases (including 137 SCLC) from the β-Carotene and 
Retinol Efficacy Trial (CARET) as part of a study on germ line variation in DNA repair 
genes and lung cancer risk (19,20). Four of the six SNPs had low MAF among SCLC 
patients (0.03–0.07) and were excluded from further investigation since a very large sample 
size would be needed to determine the effect of these SNPs. Thus only two SNPs (rs942190 
and rs2401863) were chosen for the current pooled analysis. These two SNPs are partially 
correlated, especially among individuals of European ancestry with r2 of 0.63 (r2(East Asian) = 
0.26).
The majority of genotype data for our pooled analysis were obtained from the OncoArray, a 
custom array manufactured by Illumina which contains approximately 500K SNPs that 
provide genome-wide coverage of most common genetic variants along with markers of 
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interest for common cancers (21). Genotype data from the Mayo Clinic and part of the 
genetic data from the Lunenfeld-Tanenbaum Research Institute were from existing genome-
wide association studies (GWAS). Samples from CARET participants were genotyped using 
a custom-designed 384-plex GoldenGate assay (Illumina). Samples from Japan were 
genotyped using a pre-design (for rs942190) and a custom-design (for rs2401863) TaqMan 
assay (Applied Biosystems). Race-specific genotype frequencies for both SNPs were in 
agreement with Hardy-Weinberg equilibrium (Chi-square p-values for rs942190 among 
White, rs942190 among Asian, rs2401863 among White, and rs2401863 among Asian were 
0.41, 0.14, 0.54, and 0.20, respectively).
Statistical analyses
Clinical and genotype data were harmonized across studies. Characteristics of all 898 
patients by study site are summarized in Supplementary Table S2. Race was imputed as 
White for the 96 patients of unknown race since their genotype distributions for both SNPs 
were similar to those of White patients (Supplementary Table S3). Tumor stage was 
classified as limited stage (LS or stage I–III) and extensive stage (ES or stage IV). 
Chemotherapy drug use was classified as “TOP1 inhibitor” (received any TOP1 inhibitor 
along the courses of chemotherapy), “TOP2 inhibitor” (received any TOP2 inhibitor along 
the courses of chemotherapy), and “Other/Unknown” (i.e., not known to have receives any 
TOP1 or TOP2 inhibitor). The “TOP1 inhibitor” group and the “TOP2 inhibitor” group also 
contained patients who received both TOP1 and TOP2 inhibitors, either at the same time 
(n=3) or switching from one to the other during the course of chemotherapy (n=40). The 
primary outcome was overall mortality as of 36 months post-diagnosis (when deaths are 
commonly attributed to lung cancer), measured from the date of lung cancer diagnosis until 
the date of death, last contact, or censoring at 36 months follow-up, whichever occurred first. 
Disease-specific survival was not examined, since cause of death was missing for 43% of the 
patients.
Survival analyses were performed using Kaplan-Meier survival plots and Cox proportional 
hazard regression models with a robust estimator of variance adjusting for age, sex, race 
(White vs. Asian), and tumor stage. Analyses were conducted to evaluate genotype and 
haplotype associations with overall mortality at 36 months post-diagnosis. Six patients with 
no follow-up data and two patients with no genotype data for both SNPs were excluded from 
survival analyses. Of the remaining 890 patients, six and two did not have genotype data for 
rs942190 and rs2401863, respectively. Since the SNP genotype frequencies were quite 
different between Whites and Asians, we also conducted a subgroup analysis by race for 
each SNP. Analyses were performed using STATA® 14 (StataCorp, College Station, Texas). 
Haplotype analysis was performed using the THESIAS (Testing Haplotype Effects In 
Association Studies) software version 3.1 (22), which is based on the Stochastic expectation 
maximization algorithm (23). Hazard ratios (HR) and 95% confidence intervals (CI) 
adjusting for age, sex, and tumor stage were calculated using the most common haplotype as 
the reference. Haplotype analysis was performed on White patients only since the two SNPs 
were correlated among Whites and sample sizes for Asian and other races were limited.
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Results
Selected characteristics of patients included in the survival analyses are presented in Table 2. 
The majority of patients were male, non-Hispanic White, and either current or former 
smokers. There was a slightly higher proportion of patients with limited stage than extensive 
stage SCLC. Treatment was unknown for approximately 25% of the patients. Almost 90% of 
patients with known treatment received chemotherapy, among whom most received a TOP2 
inhibitor. Approximately 90% of patients had died by the time of last follow-up and 87.5% 
of deceased patients died within 36 months after diagnosis of SCLC. The median follow-up 
time for patients who were alive at last follow-up was 73 months (ranged from 3 to 234 
months). The allele frequencies of the two SNPs differed between persons of European and 
East Asian ancestry. The MAFs of rs942190 (G allele) for White and Asian patients in this 
study were 0.49 and 0.23, respectively, and for rs2401863 (C allele) were 0.38 and 0.52, 
respectively. Mean age at diagnosis was similar for patients in each genotype group. There 
was a slightly lower proportion of female and tumors of limited stage among patients with 
the rs942190 AA genotype compared to patients with the other two rs942190 genotypes. 
The proportions of tumor stage were comparable by rs2401863 genotype.
Kaplan-Meier (KM) analyses for all patients with known vital status and genotype 
demonstrated poorer survival for patients homozygous for the minor allele (GG) of rs942190 
compared to those carrying the other two genotypes (Figure 1a). For rs2401863, better 
survival was associated with carrying both minor alleles (CC); however, the association was 
not statistically significant (Figure 1b).
The results from multivariable Cox regression analyses (Table 3) were consistent with the 
results from Kaplan-Meier analyses. Patients carrying GG of rs942190 had poorer survival 
compared to those with the AA genotype, with a HR of 1.36 (95% CI: 1.08–1.72, p-
value=0.01), but no association with survival was observed for patients with the 
heterozygous (AG) genotype (HR=1.04, 95% CI: 0.84–1.29, p-value=0.72). The HRs 
associated with the presence of the GG genotype were in the same direction for Whites and 
Asians. For rs2401863, patients carrying two minor alleles (CC genotype) tended to have 
better survival than patients carrying the AA genotype (HR=0.79, 95% CI: 0.61–1.02, p-
value=0.07); however, this inverse association with survival was observed only in White 
patients (HR=0.71, 95% CI: 0.54–0.94, p-value=0.02). The association was, if anything, in 
the opposite direction among Asian patients (HR=2.11, 95% CI: 0.90–4.95, p-value=0.09). 
The most common haplotype among White patients was the haplotype containing the G 
allele of rs942190 and the A allele of rs2401863 (the risk haplotype). The haplotype 
containing the rs942190 A allele and the rs2401863 C allele was associated with better 
survival, compared to the most common haplotype (HR=0.84; 95% CI: 0.73–0.95, p-
value=0.008).
We also examined potential functional consequences of the two SNPs using a single tissue 
expression quantitative trait loci (eQTL) analysis from the Genotype-Tissue Expression 
(GTEx) Project (www.gtexportal.org). The GTEx Project, funded by The National Institutes 
of Health Common Fund, has collected and analyzed genomic variation from blood and 
gene expression in multiple tissues of the non-diseased donor in order to determine how 
Lohavanichbutr et al. Page 5
Clin Cancer Res. Author manuscript; available in PMC 2017 December 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
genetic variation affects gene expression in human tissues (24). Based on the analysis 
available from the GTEx website, TDP1 gene expression was higher in lung tissues of 
people with the GG genotype of rs942190 than of people with AG or AA genotypes (p-value 
= 0.0008) (Figure 2). In contrast, there was minimal difference of TDP1 gene expression in 
lung tissue across rs2401863 genotypes (p-value=0.12).
Based on SNP functional prediction (http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html) 
(25), rs942190 may affect TDP1 expression by residing in a transcription factor binding site 
(TFBS). We further investigated which transcription factors (TF) bind to this region using 
data from the Encyclopedia of DNA Elements (ENCODE). The ENCODE project has 
performed a large number of ChIP-seq experiments on multiple cell lines to identify TFBSs 
across the human genome (26–28). Table 4 shows the list of 21 TFs identified by ENCODE 
that could bind to the TFBS in the location that rs942190 resides. In addition, we used a 
freely accessible web-based application called ePOSSUM (http://mutationtaster.charite.de/
ePOSSUM/) by Hombach et al. (29) to assess the impact of the T(A) and C(G) alleles of 
rs942190 on TF binding. ePOSSUM allows user to enter either the genomic position of the 
SNP (based on human genome assembly GRCh37) or the wild-type and variant sequences. 
The output shows predicted TF binding scores of 81 TFs from three sources (JASPAR, HT-
SELEX, and hPDI) as well as a summary of prediction whether the genetic alteration leads 
to the gain or loss of TF binding. Of the 21 TFs identified by ENCODE, nine have data 
available on the ePOSSUM website. Using rs942190 location (Chr14:90422414T>C) as an 
input on the website, six of the nine TFs were predicted to have a different binding affinity 
to the T(A) and C(G) allele. These included CTCF, MAX, MYBL2, RBBP5, TFAP2A, and 
TFAP2C (Table 4).
Discussion
To our knowledge, the current study is the first to investigate germline variation of TDP1 in 
relation to survival among SCLC patients. Leveraging data from ten ILCCO studies, we 
analyzed a fairly large cohort of SCLC patients with near complete follow-up at 36 months. 
Of the two SNPs examined, we found the rs942190 GG genotype to be associated with 
poorer overall survival compared to AA genotype.
Several lines of evidence support the potential function of rs942190 including the results 
from GTEx, ENCODE, and ePOSSUM. (25)It has been shown that overexpression of TDP1 
in cell lines could counteract the effect of DNA topoisomerase inhibitors (30); therefore, one 
would expect that patients with higher TDP1 in lung tissue may have more resistance to 
treatment with DNA topoisomerase inhibitors. The observed higher TDP1 expression in 
lung tissue of individuals with the rs942190 GG genotype from the GTEx analysis is in line 
with our finding that patients with the GG genotype had poorer survival than patients with 
the other two genotypes. However, this observation was based on healthy tissue; the effect of 
rs942190 GG genotype may be different in tumor tissue. No known studies have compared 
TDP1 expression in tumor versus adjacent non-tumor tissue from SCLC patients; however, 
increased TDP1 expression has been found in tumor tissue relative to adjacent non-tumor 
tissue from NSCLC patients (31,32). Conversely, we did not find a clear association between 
rs2401863 genotype and survival, which is consistent with the lack of association between 
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the rs2401863 genotype and TDP1 expression in lung tissue. Our observed association of the 
rs2401863 genotype with survival among White patients only may be due to the linkage 
with rs942190 SNP.
The difference in TDP1 expression among different rs942190 genotypes may be the result of 
differences in TF binding affinity. This SNP is located in the TFBS where several TFs bind 
(confirmed by cell line experiments from ENCODE project). At least six of them were 
predicted (based on in silico analysis) to have different binding affinity between T(A) and 
C(G) alleles of rs942190. Although these six TFs are mostly well known, the effect of these 
TFs specifically on TDP1 gene expression has not been reported. CTCF could function as an 
enhancer or repressor (33); thus the attenuation of binding may result in either increasing or 
decreasing transcription. MAX could also be either an enhancer (forming heterodimers with 
MYC, MYC-MAX) or a repressor (forming heterodimers with MAD, MAD-MAX or 
homodimers, MAX-MAX) (34–36). Overexpression of MYBL2 has been found in several 
cancer types and associated with poor patient outcomes (review in (37)). Moreover, studies 
in cell lines suggest that overexpression of MYBL2 is associated with resistance to 
chemotherapeutic agents (including etoposide) and radiation (38–40). It is plausible that one 
mechanism of resistance to topoisomerase inhibitor or radiation is through activation of 
TDP1 expression by MYBL2. Patients with the rs942190 GG genotype could have higher 
MYBL2 binding affinity, thus having higher TDP1 expression that causes their tumors to be 
relatively more resistant to the treatment. Further study is needed to investigate this 
possibility. The protein encoded by TFAP2A and TFAP2C (AP-2α and AP-2γ) could 
activate or repress transcription of their target genes (41,42). Although the effect of AP-2α 
and AP-2γ on TDP1 expression has not been reported, there was an evidence showing that 
breast cancer cell lines expressing TFAP2A and TFAP2C were more resistant to a 
topoisomerase inhibitor and radiation than constructed breast cancer cells depleting in AP-2 
function (43).
The majority of the data used in this analysis came from etiologic studies of lung cancer, and 
so the data on treatments received by patients often were limited. The treatment method and 
the name of chemotherapeutic agents used were not available for approximately 30% of 
patients in this study. The majority of patients with unavailable treatment data were from the 
Harvard cohort. However, the chemotherapy regimen most commonly used in initial 
treatment of SCLC at Harvard is etoposide (TOP2 inhibitor) plus cisplatin or carboplatin, a 
regimen similar to that of other institutions. Thus, we would expect that the majority of 
patients with unknown treatment would have received similar treatment to the rest of 
patients. Based on the available data, we explored whether the association of rs942190 with 
survival differed between patients who received TOP1 and TOP2 inhibitors. We found a 
stronger association among patients who received TOP1 inhibitor (HR comparing GG vs. 
AA adjusting for age, sex, race, and tumor stage = 1.58; 95% CI: 0.87–2.87) compared to 
those receiving TOP2 inhibitor (aHR=0.99; 95% CI: 0.73–1.34). When we excluded patients 
who received both TOP1 and TOP2 inhibitors, the magnitude of association was stronger 
among patients receiving a TOP1 inhibitor (n=47, aHR = 1.92; 95% CI: 0.73–5.06). The 
adjusted HR for those receiving a TOP2 inhibitor without a TOP1 inhibitor (n=354) was 
0.96 (95% CI: 0.69–1.33). However, since the sample size for patients who received a TOP1 
inhibitor is quite small, and important data such as chemotherapy completion and response 
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to treatment were unavailable, we are not able to conclude that the association of rs942190 
with survival differs among patients receiving different type of topoisomerase inhibitors.
In addition to repairing DNA damage produced by TOP1 and TOP2 inhibitors, an effect of 
TDP1 on DNA repair caused by radiation has been reported (11,44). Thus, we further 
explored the association of rs942190 genotype with overall survival among patients known 
to have received radiation (n=290), and found that patients with the GG genotype tended to 
have poorer survival compared to patients with the AA genotype (aHR=1.36; 95% CI: 0.95–
1.97). The association was stronger among patients who received both a TOP1 inhibitor and 
radiation therapy (n=36, aHR=4.31; 95% CI: 1.1–16.80) but not for those who received a 
TOP2 inhibitor and radiation (n=221, aHR=1.18; 95%CI: 0.78–1.81). We did not observe an 
association with survival among those who did not receive radiation therapy (n=287, aHR 
comparing rs942190 GG to AA genotype = 1.09; 95% CI: 0.76–1.55).
In conclusion, our study suggests an association between rs942190 genotype and overall 
survival at 36 months after SCLC diagnosis. The association may be different among 
patients who received different treatment regimens, with respect to both chemotherapy and 
radiation. Further assessment of the genotype-survival association in a larger study with 
more detailed and complete treatment data is needed to confirm our findings.
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Translational Relevance
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. Currently, 
there are very few markers to predict survival or to guide treatment selection for SCLC 
patients. TDP1 gene plays a role in repairing DNA topoisomerases-mediated DNA 
damage and is believed to be responsible for drug resistance to DNA topoisomerase 
inhibitors (one of the common chemotherapeutic agents used for treating SCLC). To our 
knowledge, this is the first study to investigate germ line variation of TDP1 in relation to 
survival among SCLC patients. We found rs942190 GG genotype to be associated with 
poor survival among 890 SCLC patients. If confirmed in a large study, TDP1 rs942190 
genotype may be used as a prognostic marker for patients with SCLC or a predictive 
marker for treatment response to DNA topoisomerase inhibitors.
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Figure 1. 
Kaplan-Meier survival curves among 890 patients with SCLC. A, Stratified by rs942190 
genotype. B, Stratified by rs2401863 genotype.
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Figure 2. 
Box plot from the Genotype-Tissue Expression (GTEx) Project demonstrated higher TDP1 
gene expression in lung tissues of individuals with rs942190 GG genotype compared to 
other genotypes. HomoRef, Het, and Homo Alt refer to individuals with AA, AG, and GG 
genotype, respectively.
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Table 1
Studies included in the pooled analysis
Study Name Principal Investigator Country n
CAncer de PUlmon en Asturias (CAPUA) Adonina Tardón Spain 137
Environment and Genetics in Lung Cancer Etiology (EAGLE) Maria Teresa Landi Italy 189
Epidemiology & Genetics of Lung cancer study (EGLC), Mayo Clinic Ping Yang USA 74
FHCRC Molecular Epidemiology of Lung Cancer (Ancillary study to CARET) Chu Chen USA 137
Harvard Lung Cancer Study (LCS) David C. Christiani USA 176
Japan lung cancer study Kouya Shiraishi Japan 87
Kentucky Lung Cancer Research Initiative (LCRI) Susanne M. Arnold USA 8
Liverpool Lung Project (LLP) John K. Field UK 55
Toronto lung cancer study* Rayjean J. Hung, Geoffrey Liu Canada 25
Total Lung Cancer: Molecular Epidemiology of Lung Cancer Survival (TLC) Matthew B. Schabath USA 10
*from Mount Sinai Hospital and Princess Margaret Cancer Centre (MSH-PMH) study and Great Toronto Area Study
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Table 3
Results of multivariable Cox proportional regression analyses
SNP Genotype Adjusted HR* [95% CI] p-value
rs942190 (all) AA 1.00
AG 1.04 [0.84, 1.29] 0.719
GG 1.36 [1.08, 1.72] 0.010
 White** only AA 1.00
AG 1.09 [0.87, 1.36] 0.458
GG 1.39 [1.09, 1.77] 0.008
 Asian only AA 1.00
AG 0.50 [0.21, 1.19] 0.116
GG 1.38 [0.63, 2.98] 0.420
rs2401863 (all) AA 1.00
AC 0.91 [0.76, 1.10] 0.332
CC 0.79 [0.61, 1.02] 0.071
 White** only AA 1.00
AC 0.91 [0.76, 1.11] 0.354
CC 0.71 [0.54, 0.94] 0.016
 Asian only AA 1.00
AC 0.94 [0.40, 2.20] 0.885
CC 2.11 [0.90, 4.95] 0.085
Haplotype
rs942190/rs2401863 (White** only) GA 1.00
AC 0.84 [0.73–0.95] 0.008
AA 0.88 [0.73–1.06] 0.165
GC 0.85 [0.51–1.42] 0.541
*
adjusted for age, sex, race, and tumor stage for all patients and adjusted for age, sex, and tumor stage for subgroup analyses
**including White and unknown race (imputed as White)
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Table 4
Transcription factors (TFs) identified by ENCODE that could bind to the transcription factor binding site at 
the location that rs942190 resides and the prediction of TF binding comparing between T and C allele of 
rs942190 based on ePOSSUM.
Transcription Factor Summary prediction based on ePOSSUM
AP-2gamma not available on ePOSSUM
ATF2 not available on ePOSSUM
CCNT2 not available on ePOSSUM
CHD1 not available on ePOSSUM
CTCF attenuation of TF binding for C allele compared to T allele
E2F1 no definite result
E2F6 no definite result
ELF1_(SC-631) not available on ePOSSUM
HA-E2F1 not available on ePOSSUM
HDAC1 not available on ePOSSUM
MAX attenuation of TF binding for C allele compared to T allele
MYBL2 enhancement of TF binding for C allele compared to T allele
MYC not available on ePOSSUM
PHF8 not available on ePOSSUM
Pol2 not available on ePOSSUM
Pol2-4H8 not available on ePOSSUM
POLR2A not available on ePOSSUM
RBBP5 enhancement of TF binding for C allele compared to T allele
TCF3 no definite result
TFAP2A enhancement of TF binding for C allele compared to T allele
TFAP2C enhancement of TF binding for C allele compared to T allele
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